INS and obesity disorder: Previous studies demonstrated an improved insulin secretion in the presence of the non-selective α2-adrenoceptor antagonist—yohimbine in diabetic patients [27], as well as the reduction of the glucose level by yohimbine in animal model of obesity induced by a high-fat diet [20] and in ob/ob mice (results submitted for publication).